Latest articles about pneumococcal disease
The vast majority of Gavi-supported countries have introduced pneumococcal vaccines, reaching more than 215 million children by the end of 2019 – and growing pneumococcal vaccine coverage in Gavi-supported countries above the worldwide average.
MORE THAN 215 MILLION CHILDREN REACHED
By the end of 2019, Gavi support had helped countries immunise more than 215 million children across 60 lower-income countries against pneumococcal disease.
In 2019, for the first time, pneumococcal vaccine coverage in Gavi-supported countries was higher than the worldwide average: 49% in 2019, up from 37% in 2015 and above the global average of 48%. This reflects a decade of progress and hard work by countries and Vaccine Alliance partners to support the introduction of pneumococcal vaccine into routine immunisation programmes and to scale up coverage.
Gavi contributed to the development of UNICEF and WHO’s integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD), which in 2013 set a target to reduce mortality from pneumonia in children aged under five to fewer than 3 per 1,000 live births.
PNEUMOCOCCAL ADVANCE MARKET COMMITMENT (AMC)
Pneumococcal conjugate vaccines (PCV), which protect against the main cause of pneumonia, are complex to develop and produce. In the past, they may have taken up to 15 years to reach lower-income countries. Thanks to the Vaccine Alliance, Gavi countries can access the newest vaccines at the same time as high-income countries.
In its eleventh year of implementation, the Advance Market Commitment (AMC) for pneumococcal vaccines has facilitated the procurement of a total of 161 million doses of PCV for lower-income countries, an 8% increase from 2018. The introduction of these vaccines is largely thanks to the generosity of Italy, the United Kingdom, Canada, the Russian Federation, Norway and the Bill & Melinda Gates Foundation. They have together contributed more than US$ 1.3 billioni to the Pneumococcal AMC.
ROLL-OUT ACROSS THREE CONTINENTS
Gavi aimed to support pneumococcal vaccine introductions in 45 countries by 2015. We reached this target already in November 2014, 13 months ahead of schedule. By the end of 2019, 60 Gavi-supported countries – more than 80% of those eligible to do so – had introduced pneumococcal conjugate vaccine (PCV) into their routine immunisation programmes.
Mongolia, which transitioned out of Gavi support in 2015, rolled out the vaccine in June 2016, becoming the first transitioned country to fully self-fund its pneumococcal vaccine programme; it was followed by Bhutan in January 2019. In 2020, three countries that have transitioned out of Gavi support – Indonesia, Timor-Leste and Ukraine – requested and received access to the AMC PCV price and are expected to introduce PCV into their routine immunisation programmes in the next two years.